Objective-Dysregulation of tumour necrosis factor a (TNFa) production is thought to be important in rheumatoid arthritis. Since pentoxifylline and thalidomide inhibit endotoxin induced TNF production in vitro, these drugs were tested in an open study in rheumatoid arthritis patients to assess toxicity, the effect on TNF production, and the antiarthritic effects. Methods-12 patients with active rheumatoid arthritis were treated with 1200 mg pentoxifylline and 100 mg thalidomide a day during 12 weeks. In addition, TNF production was assessed by ex vivo whole blood cultures stimulated with endotoxin.
Reszdts-Adverse events such as xerostomia, drowsiness, and constipation occurred in almost all patients, which led to discontinuation in three. The drugs halved the TNF production capacity during treatment (ANOVA, P < 0.03) whereas production capacity of interleulin (IL) 6 , IL-10, and IL-12 was not affected. Of the nine patients who completed the study, five fulfilled the ACR -200/o response criteria after 12 weeks oftreatment.
Conclusions-Although pentoxifylline/thalidomide reduced the production capacity of TNF, the benefitiside effects ratio was poor due to multiple adverse effects, while clinical observation suggests limited efficacy.
(Ann Rheum Dis 1996;55: [833] [834] [835] [836] The identification of tumour necrosis factor a (TNFa) as one of the key mediators of inflammation in rheumatoid arthritis has led to randomised trials using anti-TNFa monoclonal antibody (Mab) which were reported to have beneficial results.'2 These results support the hypothesis that reducing TNF concentrations is an attractive goal in the treatment of rheumatoid arthritis.
TNF is an inducible cytokine that is not produced in resting cells. Stimulation of monocytes by endotoxin is used as a model system to select drugs that inhibit TNF production. Pentoxifylline, a methylxanthine derivative and phosphodiesterase inhibitor, reduces TNF production in cultured monocytes by inhibition Patients were always evaluated between 9 and 11 am and phlebotomy was performed at that time. Patients were also evaluated as responders or non-responders according to the modified American College of Rheumatology (ACR) core set of improvements.
Cytokine production TNFa, interleukin (IL) 10, IL-12, and IL-6 production capacity was evaluated using a whole blood stimulation assay as described. (range 9-32). In order to detect changes despite this variability, blood was obtained before the medication, two times during medication, one day after cessation of medication, and four weeks after discontinuation of the medication. Table 1 shows that the amount of TNF produced was reduced significantly during treatment with pentoxifylline/ thalidomide (P = 0.01, ANOVA). The amount of TNF produced in the whole blood cultures before the study (at week 0) was less than after the study but the change was not significant (P = 0.33). If TNF was measured by a bioassay instead ofan EA, inhibition ofTNF production was also found (ANovA, P = 0.037) (table 1). To assess the specificity of pentoxifylline/ thalidomide treatment for reducing TNF production, several other proinflammatory cytokines (IL-6, IL-12) and anti-inflammatory cytokines (IL-10) were measured in the whole blood culture supernatants. (table 3) . Since the hypothesis guiding this trial was a putative relation between inhibition of production capacity of TNF and antiarthritic effects the correlation was tested between the clinical response and decrease in TNF production capacity. Such a correlation was not observed.
Also no correlation was observed between the decrease in TNF production capacity and reduction in swollen joint count (correlation -0.57) tender joint count (correlation 0.8), restricted motion (correlation 0.18), grip strength (correlation 0.39), or disease assessment judgements (-0.76). Table 3 shows laboratory variables during treatment. The trend in the laboratory variables was an increase in acute phase reactants. Some of the variables changed significantly, such as haemoglobin and thrombocytes, whereas others changed nonsignificantly (C reactive protein, ESR, IL-6, and albumin). These changes might be caused by an effect of the medication, for example, on the liver or a direct effect on cytokine production. The IL-6 concentration in plasma was not significantly increased during treatment. No significant correlations were found between the changes in production capacity of IL-6, IL-1 0, or IL-12 and the differences in concentrations of acute phase proteins before and during treatment.
CHANGES IN ACUTE PHASE PROT1EINS DURING PENTOXIFYLLINE/THALIDOMIDE TREATMENT
The hypothalamic-pituitary axis is independently activated by the inflammatory cytokines TNFcX, IL-1, and IL-6.14 During pentoxifylline/thalidomide the cortisol levels were increased, although not significantly. Finally, TNF concentrations in plasma were measured. Table 3 shows that the amounts of TNF in plasma were low and variable. No significant changes could be measured during the course of the study.
Discussion
This study showed that the combination pentoxifylline and thalidomide is rather toxic. Symptoms related to side effects were observed in the majority of the patients. The incidence of side effects was similar to that in other studies except for a higher incidence of xerostomia.1113 The efficacy of simultaneous treatment with pentoxifylline and thalidomide in reducing TNF production was observed during treatment. This inhibition was specific, since production of IL-6, IL-i 0, and IL-12 was not affected.
The clinical effects of thalidomide/ pentoxifylline were such that 55% of the patients reached the 20% improvement criterion. This could be due to a placebo effect, regression to the mean, or a real effect. The absence of a correlation between clinical effect and the effect on TNF production does not suggest that the decrease in TNF producing capacity is causally related to reduction in disease activity, for example the swollen joint count. Moreover, the changes in the plasma IL-6, thrombocyte count, C reactive protein, ESR, albumin, haemoglobin, and cortisol were not suggestive of a reduction in TNF production in the arthritic joints. To clarify the issue of the clinical efficacy of pentoxifylline/ thalidomide in rheumatoid arthritis a placebo controlled trial is necessary.
The relation between the reduction of endotoxin induced TNF production measured ex vivo and a possibly reduced TNF production in the arthritic joint or an antiarthritic effect is uncertain. In this study no such relations were found. In another study of pentoxifylline in rheumatoid arthritis, seven out of 16 patients improved but there was also no observed correlation between clinical improvement and reduction in TNF production.7. This lack of correlation can be explained by sample size or might suggest that inhibition in the endotoxin induced TNF production is not relevant for the inflammatory process in rheumatoid arthritis. This interpretation contrasts with the beneficial effects of phosphodiesterase inhibitors in murine models of arthritis in which inhibition of endotoxin induced TNF production occurred simultaneously with antiarthritic effects. In numerous clinical situations pentoxifylline is used to reduce TNF mediated effects. However, no data are available showing that a reduction in TNF production affects the production of acute phase proteins. This phase I study was initiated on the basis that continuous production of TNF in the arthritic joints could be inhibited in a similar way to the TNF produced in endotoxin stimulated whole blood cultures. However, the lack of association between reduction in TNF production in endotoxin stimulated whole blood cultures and laboratory variables reflecting joint inflammation or clinical improvement brings the value of this substitute index of pharmacological efficacy into question. A 
